HomeCompareOPHLY vs SBUX

OPHLY vs SBUX: Dividend Comparison 2026

OPHLY yields 3.41% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OPHLY wins by $782.42M in total portfolio value
10 years
OPHLY
OPHLY
● Live price
3.41%
Share price
$5.29
Annual div
$0.18
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$782.58M
Annual income
$740,792,960.47
Full OPHLY calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — OPHLY vs SBUX

📍 OPHLY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOPHLYSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OPHLY + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OPHLY pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OPHLY
Annual income on $10K today (after 15% tax)
$289.50/yr
After 10yr DRIP, annual income (after tax)
$629,674,016.40/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, OPHLY beats the other by $629,618,052.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OPHLY + SBUX for your $10,000?

OPHLY: 50%SBUX: 50%
100% SBUX50/50100% OPHLY
Portfolio after 10yr
$391.37M
Annual income
$370,429,400.30/yr
Blended yield
94.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

OPHLY
Analyst Ratings
2
Sell
Consensus: Sell
Altman Z
5.0
Piotroski
8/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OPHLY buys
0
SBUX buys
0
No recent congressional trades found for OPHLY or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOPHLYSBUX
Forward yield3.41%2.75%
Annual dividend / share$0.18$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%48.3%
Portfolio after 10y$782.58M$157.5K
Annual income after 10y$740,792,960.47$65,840.13
Total dividends collected$779.53M$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusSellBuy

Year-by-year: OPHLY vs SBUX ($10,000, DRIP)

YearOPHLY PortfolioOPHLY Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$11,381$681.17$11,107$407.21+$274.00OPHLY
2$13,627$1,449.07$12,512$626.87+$1.1KOPHLY
3$17,824$3,243.01$14,366$978.69+$3.5KOPHLY
4$27,000$7,928.61$16,929$1,557.50+$10.1KOPHLY
5$51,340$22,449.56$20,658$2,543.80+$30.7KOPHLY
6$134,722$79,788.74$26,406$4,302.22+$108.3KOPHLY
7$535,510$391,357.72$35,877$7,622.00+$499.6KOPHLY
8$3,480,692$2,907,695.93$52,741$14,352.64+$3.43MOPHLY
9$39,050,210$35,325,869.63$85,676$29,243.03+$38.96MOPHLY
10$782,576,685$740,792,960.47$157,513$65,840.13+$782.42MOPHLY

OPHLY vs SBUX: Complete Analysis 2026

OPHLYStock

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.

Full OPHLY Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this OPHLY vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OPHLY vs SCHDOPHLY vs JEPIOPHLY vs OOPHLY vs KOOPHLY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.